Best Practice & Research Clinical Haematology
Volume 20, Issue 4 , Pages 701-715 , December 2007

Bortezomib in multiple myeloma

  • J.F. San Miguel, MD, PhD

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +34923291384, Fax: +34923294624.

References 

  1. Kyle R, Rajkumar SV. Múltiple Myeloma. The New England Journal of Medicine. 2004;351(18):1860–1873
  2. Adams U, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel of potent and effective antitumor agents. Cancer Research. 1999;59:2615–2622
  3. Adams J. The proteasome; a suitable antineoplastic target. Nature Reviews Cancer. 2004;4:349–360
  4. Glickman MH, Ciechanovr A. The ubiquitin-proteasome proteolytic pathway; destruction for the sake of construction. Physiological Reviews. 2002;82:373–428
  5. Groll M, Ditzel L, Lowe J, et al. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature. 1997;386:463–471
  6. Voorhees PM, Orlowski RZ. The proteasome and proteasome inhibitors in cancer therapy. Annual Review of Pharmacology and Toxicology. 2006;46:189–213
  7. San Miguel JF, Gutiérrez N, García-Sanz R, et al. Thalidomide and new drugs for treatment of multiple myeloma. The Hematology Journal. 2003;4:201–207
  8. Mitsiades CS, Mitsiades N, Hideshima T, et al. Proteasome inhibition as a therapeutic strategy for hematologic malignancies. Expert Review of Anticance Therapy. 2005;5:465–476
  9. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Research. 2001;61:3071–3076
  10. Lee AH, Iwakoshi NN, Anderson KC, et al. Proteasome inhibitor disrupt the unfolded protein response in myeloma cells. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:9946–9951
  11. Hideshima T, Chauhan D, Hayashi T, et al. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent down regulation of gp130 in multiple myeloma. Oncogene. 2003;22(52):8386–8393
  12. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Research. 2002;62(17):4996–5000
  13. Aghajanian C, Soignet S, Dizon DS, et al. A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumour malignancies. Clinical Cancer Research. 2002;8:2505–2511
  14. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. Journal of Clinical Oncology. 2002;20:4420–4427
  15. Papandreu C, Daliani KK, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumours with observations in androgen-independent prostate cancer. Journal of Clinical Oncology. 2004;22:2108–2121
  16. Adams J. Development of the proteasome inhibitor PS-341. Oncologist. 2002;7(1):9–16
  17. Pekol-Ohm T, Daniels JS, Labutti J, et al. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metabolism and Disposition. 2005;33:771–777
  18. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. The New England Journal of Medicine. 2003;348(26):2609–2617
  19. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. British Journal of Haematology. 2004;127(2):165–172
  20. Richardson PG, Sonnelvedld P, Schuster MW, et al. Bortezomib or High-dose dexamethasone for relapsed multiple myeloma. The New England Journal of Medicine. 2005;352:2487–2498
  21. Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007;21:151–157
  22. Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumour cells to chemotherapeutic agents. Clinical Cancer Research. 2003;9(3):1136–1144
  23. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101:2377–2380
  24. Orlowski RZ, Voorhees P, Reynaldo A, et al. Phase I trial of the proteasome inhibitor Bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood. 2005;105:3058–3065
  25. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized Phase III study of pegilated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892–3901
  26. Berenson JR, Yang HH, Sadler K, et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Journal of Clinical Oncology. 2006;24(6):937–944
  27. Popat R, Williams C, Cook M, et al. A Phase I/II Trial of bortezomib, low dose intravenous melphalan and dexamethasone for patients with relapsed multiple myeloma. Blood. 2006;108(11):3542;Abstract
  28. Reece DE, Piza G, Trudel S, et al. A phase i–ii trial of bortezomib plus oral cyclophosphamide and prednisone for relapsed/refractory multiple myeloma. Blood. 2006;108(11):3536;Abstract
  29. Kropff M, Bisping G, Liebisch P, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol. 2007;138:330–337
  30. Davies FE, Wu P, Jenner M, et al. The combination of cyclophosphamide, velcade and dexamethasone (VCD) induces high response rate and comparable toxicity compared to velcade alone and velcade plus dexamethasone. Haematologica. 2007;92:1149–1150
  31. Zangari M, Barlogie B, Burns MJ, et al. Velcade (V)–thalidomide (T)–dexamethasone (D) for advanced and refractory multiple myeloma (MM): long-term follow-up of phase I–II trial UARK 2001-37: Superior outcome in patients with normal cytogenetic and no prior T. Blood. 2005;106:2552;Abstract
  32. Hollmig K, Stover J, Talamo G, et al. Bortezomib (velcadeTM) + adriamycinTM + thalidomide + dexamethasone (VATD) as an effective regimen in patients with refractory or relapsed multiple myeloma (MM). Blood. 2004;104(11):2399;Abstract
  33. Chanan-Khan A, Miller KC. Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma. Leukemia and Lymphoma. 2005;46(7):1103–1104
  34. Palumbo A, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisone and thalidomide for relapsed multiple myeloma. Blood. 2007;109:2767–2772
  35. Terpos E, Anagnostopoulos A, Heath D, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) is an effective regimen for relapsed/refractory myeloma and reduces serum levels of Dickkopf-1, RANKL, MIP-1α and angiogenic cytokines. Blood. 2006;108(11):3541;Abstract
  36. Richardson PG, Jagannath S, Avigan DE, et al. Bortezomib and lenalidomide plus (Vel-Rev) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial. Blood. 2006;108(11):404;Abstract
  37. Richardson P, Chanan-Khan A, Schlossman R, et al. Phase II trial of single agent bortezomib (VELCADE®) in patients with previously untreated multiple myeloma (MM). Blood. 2004;104(11):336;Abstract number
  38. Dispenzieri A, Zhang L, Fonseca R, et al. Single agent bortezomib is associated with a high response rate in patients with high risk myeloma. A Phase II study from the Eastern Cooperative Oncology Group (E2A02). Blood. 2006;108(11):3527;Abstract
  39. Jagannath S, Wolf H, Camacho E, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. British Journal of Haematology. 2005;129:776–783
  40. Jagannath S, Durie B, Wolf H, et al. Long-term follow-up of patients treated with bortezomib alone and in combination with dexamethasone as frontline therapy for multiple myeloma. Blood. 2006;108(11):796;Abstract
  41. Harousseau JL, Attal M, Leleu X, et al. Bortezomib (VELCADE®) plus dexamethasone as induction treatment prior to autologous stem cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma: preliminary results of an IFM phase II study. Hematologica. 2006;91(11):1498–1505
  42. Harousseau JL, Marit G, Caillot D, et al. VELCADE/dexamethasone (Vel/Dex) Versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): an interim analysis of the IFM 2005-01 randomized multicenter phase III trial. Blood. 2006;108(11):56;Abstract
  43. Rosiñol L, Oriol A, Mateos MV, et al. Phase II Pethema trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem cell transplantation in younger patients with Multiple Myeloma: Efficacy and clinical implications of tumor response kinetics. J Clin Oncol. 2007;25(28):4452–4458
  44. Oarkowee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma. British Journal of Haematology. 2005;129:755–762
  45. Popat R, Oakervee HE, Curry N, et al. Reduced dose PAD combination therapy (PS-341/bortezomib, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma. Blood. 2005;106(11):717;Abstract
  46. Jakuboviak AJ, Al-Zoubi A, Kendall T, et al. High rate of complete and near complete responses (CR/nCR) after initial therapy with bortezomib (Velcade®), Doxil®, and dexamethasone (VDD) is further increased after autologous stem cell transplantation (ASCT). Blood. 2006;108(11):3096;Abstract
  47. Wang M, Giralt S, Delasalle K, et al. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology. 2007;12(3):235–239
  48. Badros A, Goloubeva O, Fenton R, et al. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma. Clinical Lymphoma and Myeloma. 2006;7(3):210–216
  49. Mateos MV, Hernández JM, Hernández MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II trial. Blood. 2006;108:2165–2172
  50. Millennium Pharmaceuticals, Inc . VelcadeTM (bortezomib) for injection. Prescribing information. Cambridge, MA: Millennium Pharmaceuticals, Inc.; 2004;
  51. Jagannath S, Barlogie B, Berenson JR, et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer. 2005;103:1195–1200
  52. Chanan-Khan A, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007;109:2604–2606
  53. San Miguel JF, Bladé J, Boccadoro M, et al. A practical update on the use of bortezomib in the management of multiple myeloma. The Oncologist. 2006;11:51–61
  54. Rosiñol L, Montoto S, Cibeira MT, et al. Bortezomib-induced severe hepatitis in multiple myeloma: a case report. Archives of Internal Medicine. 2005;165:464–465
  55. Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005;106:3777–3784
  56. Sezer O, Vesole DH, Singhal S, et al. Bortezomib-induced tumor lysis syndrome in multiple myeloma: brief communication. Clinical Lymphoma and Myeloma. 2006;7(3):233–235

PII: S1521-6926(07)00068-0

doi: 10.1016/j.beha.2007.09.003

Best Practice & Research Clinical Haematology
Volume 20, Issue 4 , Pages 701-715 , December 2007

Article Tools

* Image Usage & Resolution